GSK partners with research councils in U.K. and South Africa on non-communicable diseases
GlaxoSmithKline has announced an $8 million collaboration with the U.K. and South African Medical Research Councils, to support much-needed research into non-communicable diseases (NCDs) in Africa, as part of GSK’s Africa NCD Open Lab initiative.
The funding was pledged by James Duddridge, the U.K. foreign office minister responsible for Africa, and Naledi Pandor, South Africa’s minister for science and technology, as part of a broader collaboration between the two countries on scientific research. It will be used to support researchers from South African institutions conducting research projects in NCDs, aligned with the objectives of GSK’s Africa NCD Open Lab.
Four million dollars will be provided by the U.K. Medical Research Council, via the U.K. Newton Fund —a government fund established in 2013 to develop science and innovation partnerships that promote the economic development and welfare of developing countries—and approximately $2.4 million will come from the South African Medical Research Council. GSK will provide an additional $1.6 million, together with a commitment of internal R&D expertise, to support projects within South Africa.
GSK also will commit a further $6.4 million to support successful proposals for NCD research from selected countries elsewhere in sub-Saharan Africa. The call for proposals from these countries will launch later in 2014.
The Africa NCD Open Lab was established by GSK earlier this year as part of a series of strategic investments in sub-Saharan Africa. In this region, and across developing countries, non-communicable diseases, such as cancer and diabetes, pose an increasing threat, and more needs to be done to understand the specific variations of disease in this setting.
The Africa NCD Open Lab aims to address this through the creation of an innovative research network that will see GSK scientists collaborate with researchers across Africa on high-quality epidemiological, genetic and interventional research from its hub at GSK’s Stevenage R&D facility in the U.K. The aim is that this will help build local expertise, creating a new generation of African NCD experts while instilling a deep vein of “African thinking” within GSK’s own R&D organization.
This builds on the success of GSK’s Open Lab in Tres Cantos, Spain, established in 2010 to give independent researchers access to GSK facilities, resources and knowledge to help them advance their own projects in to diseases of the developing world, such as malaria, tuberculosis and leishmaniasis. Since then, 14 projects from world-class institutions have completed, progressing much needed research into diseases of the developing world.
Patrick Vallance, president of pharmaceutical R&D at GSK, said, “We believe that by providing support to African institutions as they carry out their own research into the chronic disease variants that most affect the African people, the NCD Open Lab will play a key role in helping to tackle disease in this area.”
An official call for proposals, seeking interest from researchers from South Africa and wider sub-Saharan Africa, will be launched later in 2014, to begin in the second quarter of 2015.